BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF), a biotech company developing next-generation cancer treatments, has reported positive results from its preclinical study of BVX001.
Researchers compared the BiVictriX discovery to Mylotarg, the only approved antibody drug conjugate for the treatment of acute myeloid leukaemia (AML).
They found that BVX001 was well-tolerated and showed a "highly favourable" safety profile.
This is in contrast to Mylotarg, which has the potential to reduce normal neutrophil counts, raising the risk of fatal infections in patients with AML.
The results suggest that BiVictriX's Bi-Cygni platform offers the potential to deliver more effective and safer cancer treatments.
Chief executive Tiffany Thorn said: "Receiving these positive preclinical safety results reinforces the superior cancer selectivity of our Bi-Cygni approach.
“These findings move us another step closer to the clinic and provide further evidence that our first-in-class platform offers the potential to deliver the next generation of highly selective, anti-cancer therapies."
The latest update follows last month’s announcement that it had found a development lead for the BVX001 programme.
BiVictriX is now focused on delivering additional in vivo efficacy data to further strengthen the preclinical data package for the drug.
Using its Bi-Cygni technology, the group is developing drugs that are highly targeted, meaning that they do not carry the toxic side-effects of existing treatments.